1,804 results on '"Quaglino, P"'
Search Results
2. Fibroblasts’ secretome from calcified and non-calcified dermis in Pseudoxanthoma elasticum differently contributes to elastin calcification
- Author
-
Francesco Demetrio Lofaro, Sonia Costa, Maria Luisa Simone, Daniela Quaglino, and Federica Boraldi
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Abstract Pseudoxanthoma elasticum (PXE) is a rare disease characterized by ectopic calcification, however, despite the widely spread effect of pro/anti-calcifying systemic factors associated with this genetic metabolic condition, it is not known why elastic fibers in the same patient are mainly fragmented or highly mineralized in clinically unaffected (CUS) and affected (CAS) skin, respectively. Cellular morphology and secretome are investigated in vitro in CUS and CAS fibroblasts. Here we show that, compared to CUS, CAS fibroblasts exhibit: a) differently distributed and organized focal adhesions and stress fibers; b) modified cell-matrix interactions (i.e., collagen gel retraction); c) imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases; d) differentially expressed pro- and anti-calcifying proteoglycans and elastic-fibers associated glycoproteins. These data emphasize that in the development of pathologic mineral deposition fibroblasts play an active role altering the stability of elastic fibers and of the extracellular matrix milieu creating a local microenvironment guiding the level of matrix remodeling at an extent that may lead to degradation (in CUS) or to degradation and calcification (in CAS) of the elastic component. In conclusion, this study contributes to a better understanding of the mechanisms of the mineral deposition that can be also associated with several inherited or age-related diseases (e.g., diabetes, atherosclerosis, chronic kidney diseases).
- Published
- 2024
- Full Text
- View/download PDF
3. New imputation methodologies for genotype-by-environment data: an extensive study of properties of estimators
- Author
-
Angelini, Julia, Cervigni, Gerardo D. L., and Quaglino, Marta B.
- Published
- 2024
- Full Text
- View/download PDF
4. Phytoplasma identification in pome fruit trees and Cacopsylla bidens (Hemiptera: Psyllidae) in Jordan
- Author
-
Alloush, Asem Habes Abu, Bianco, Piero Attilio, Alma, Alberto, Tedeschi, Rosemarie, and Quaglino, Fabio
- Published
- 2023
- Full Text
- View/download PDF
5. Multicenter Comparison of Aortic Arch Aneurysms and Dissections Zone 0 Hybrid and Total Endovascular Repair
- Author
-
Frola, Edoardo, Mortola, Lorenzo, Ferrero, Emanuele, Ferri, Michelangelo, Apostolou, Dimitrios, Quaglino, Simone, Maione, Massimo, and Gaggiano, Andrea
- Published
- 2023
- Full Text
- View/download PDF
6. Identification of phytoplasmas associated with grapevine ‘bois noir’ and flavescence dorée in inter-row groundcover vegetation used for green manure in Franciacorta vineyards
- Author
-
Moussa, Abdelhameed, Guerrieri, Enea, Torcoli, Sara, Serina, Flavio, Quaglino, Fabio, and Mori, Nicola
- Published
- 2023
- Full Text
- View/download PDF
7. Head–neck melanoma: Clinical, histopathological and prognostic features of an Italian multicentric study
- Author
-
Giusy Schipani, Steven P. Nisticò, Pietro Quaglino, Simone Ribero, Giuseppe Gallo, Vincenzo Maione, Giampiero Girolomoni, Paolo Rosina, Mauro Alaibac, Francesco Messina, Alessandro Gatti, Giuseppe Stinco, Cinzia Buligan, Sara Bassoli, Francesca Farnetani, Alessandro Borghi, Davide Melandri, Riccardo Sirna, Luca Feci, Stefano Simonetti, Luca Stingeni, Annamaria Offidani, Valerio Brisigotti, Anna Campanati, Stefano Calvieri, Giulia Spallone, Elisabetta Botti, Vincenzo Panasiti, Gianluca Pagnanelli, Massimiliano Scalvenzi, Gabriella Fabbrocini, Claudia Costa, Vincenzo Schirripa, Francesco Borgia, Laura Atzori, Elisabetta Scali, Maria Passante, Fabrizio Guarneri, and Cataldo Patruno
- Subjects
head–neck melanoma ,location of melanoma ,Dermatology ,RL1-803 ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Background Primitive location of melanoma could be a relevant prognostic factor. As regards the scalp, some studies indicate a particularly aggressive biological behaviour for this anatomical localisation. Objectives In this multicentric study, data regarding head–neck melanoma (HNM) have been revised. Methods The design of the study included two main phases. In this retrospective study, data regarding HNM have been collected and analysed. Results In summary, our data suggest that the posterior neck is the area most affected by thicker melanomas. Cheeks and neck melanoma are associated with reduced disease‐free years of life and overall survival compared with all other sites of HNM. Conclusions This study provides useful information in defining the clinical features of HNM, thus improving diagnosis and treatment strategies.
- Published
- 2024
- Full Text
- View/download PDF
8. Cutaneous T-cell Lymphoma Diagnostic and Therapeutic Trends amidst the COVID-19 Pandemic
- Author
-
Gabriele Roccuzzo, Nicole Macagno, Cristina Sarda, Jelena Pisano, Simone Ribero, Paolo Fava, and Pietro Quaglino
- Subjects
ctcl ,covid19 ,lymphoma ,mogamulizumab ,brentuximab ,photherapy ,Dermatology ,RL1-803 - Abstract
Abstract is missing (Short communication)
- Published
- 2024
- Full Text
- View/download PDF
9. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
- Author
-
Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, and Keith T. Flaherty
- Subjects
Medicine (General) ,R5-920 - Published
- 2024
- Full Text
- View/download PDF
10. Clinical features of thyroid cancer in paediatric age. Experience of a tertiary centre in the 2000–2020 period
- Author
-
Tuli, Gerdi, Munarin, Jessica, Matarazzo, Patrizia, Marino, Antonio, Corrias, Andrea, Palestini, Nicola, Quaglino, Francesco, and De Sanctis, Luisa
- Published
- 2023
- Full Text
- View/download PDF
11. Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program
- Author
-
Quaglino P, Ascierto PA, Consoli F, Queirolo P, Spagnolo F, Morelli MF, Berardi R, Chiarion-Sileni V, Tucci M, Troiani T, Melotti B, Rossi E, Mandala M, Rinaldi G, Marcon IG, Pizzuti M, and Del Vecchio M
- Subjects
braf mutation ,dabrafenib ,melanoma ,real-world ,trametinib ,managed access program ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Pietro Quaglino,1 Paolo A Ascierto,2 Francesca Consoli,3 Paola Queirolo,4 Francesco Spagnolo,5 Maria Francesca Morelli,6 Rossana Berardi,7 Vanna Chiarion-Sileni,8 Marco Tucci,9 Teresa Troiani,10 Barbara Melotti,11 Ernesto Rossi,12 Mario Mandala,13 Gaetana Rinaldi,14 Ilaria Gioia Marcon,15 Matteo Pizzuti,15 Michele Del Vecchio16 1Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy; 2Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy; 3Department of Oncology, ASST Spedali Civili, Brescia, Italy; 4Oncology Division, Policlinico San Martino IRCCS, Genova, Italy, and Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy; 5Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 6Department of Oncology and Dermatological Oncology, Istituto Dermopatico dell’Immacola, Rome, Italy; 7Università Politecnica delle Marche – Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy; 8Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; 9Medical Oncology Unit, Department of Interdisciplinary Medicine, University of Bari ‘Aldo Moro’, Bari, Italy; 10Faculty of Medicine, Second University of Naples, Naples, Italy; 11Medical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 12Medical Oncology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy; 13Division of Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy, and University of Perugia, Perugia, Italy; 14UOC Oncologia Medica Aoup Paolo Giaccone, Palermo, Italy; 15Novartis Farma S.p.A, Milan, Italy; 16Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyCorrespondence: Michele Del Vecchio, Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1 20133, Milano, Italy, Tel +39 2.23902557, Email Michele.DelVecchio@istitutotumori.mi.itPurpose: Real-world data from patients with BRAFV600-mutated, resected, stage III melanoma treated with dabrafenib plus trametinib as adjuvant targeted therapy are limited, and it is important to gain an understanding of the characteristics of this patient population, as well as of the patient journey. Here we aimed to describe the characteristics, dosage reductions and discontinuations in patients with BRAFV600E/K-mutated melanoma receiving adjuvant dabrafenib plus trametinib after surgical resection through an Italian managed access program (MAP).Patients and Methods: Eligible patients had completely resected cutaneous melanoma with confirmed BRAF V600E or V600K mutation, or initially resectable lymph node recurrence after a diagnosis of stage I or II melanoma. The starting dose of dabrafenib and trametinib was 150 mg twice daily and 2 mg once daily, respectively.Results: A total of 557 patients received dabrafenib plus trametinib through the MAP (stage III resected disease at inclusion, 554). Median age was 54.0 years, and 40.2% of patients were female. The proportion of all treated patients who required a dose reduction was low (10.8%) as was the proportion of patients who discontinued treatment (13.5%). The main reason for treatment discontinuation was adverse events (36.0%).Conclusion: New treatments, including BRAF-targeted therapies and immunotherapy, have transformed the natural history of melanoma. This is the largest study to date describing patients treated with dabrafenib plus trametinib in routine clinical practice in Italy between 2018 and 2019. Results highlight the characteristics of the patients treated and their journey, as well as the tolerable safety profile of dabrafenib plus trametinib in a real-world patient population.Keywords: BRAF mutation, dabrafenib, melanoma, real-world, trametinib, managed access program
- Published
- 2023
12. Phytoplasmas: Molecular Characterization and Host–Pathogen Interactions
- Author
-
Wei Wei, Yan Zhao, and Fabio Quaglino
- Subjects
n/a ,Biology (General) ,QH301-705.5 - Abstract
Phytoplasmas are small, wall-less bacteria that infect many plant species and multiply within phloem-feeding insects of the Hemiptera order [...]
- Published
- 2024
- Full Text
- View/download PDF
13. Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology
- Author
-
Queirolo, P., Cinquini, M., Argenziano, G., Bassetto, F., Bossi, P., Boutros, A., Clemente, C., de Giorgi, V., Del Vecchio, M., Patuzzo, R., Pennachioli, E., Peris, K., Quaglino, P., Reali, A., Zalaudek, I., and Spagnolo, F.
- Published
- 2024
- Full Text
- View/download PDF
14. Validation of airway porcine epithelial cells as an alternative to human in vitro preclinical studies
- Author
-
Genna, Vincenzo Giuseppe, Adamo, Davide, Galaverni, Giulia, Lepore, Fabio, Boraldi, Federica, Quaglino, Daniela, Lococo, Filippo, and Pellegrini, Graziella
- Published
- 2023
- Full Text
- View/download PDF
15. Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)
- Author
-
Diego Orsini, Piergiorgio Malagoli, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Valentina Dini, Maria Esposito, Maria C. Fargnoli, Francesca M. Gaiani, Luigi Gargiulo, Paolo Gisondi, Alessandro Giunta, Luciano Ibba, Claudia Lasagni, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Alessandra Narcisi, Annamaria Offidani, Giovanni Paolino, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Chiara Assorgi, and Antonio Costanzo
- Subjects
immunomodulatory therapies ,inflammatory skin diseases ,psoriasis ,psoriasis treatment ,Dermatology ,RL1-803 - Abstract
Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis, their efficacy in challenging-to-treat areas remains inadequately explored. Intriguingly, studies have shown that interleukin (IL)-17 inhibitors exhibit effectiveness in addressing genital psoriasis. Objectives: We aimed to determine the effectiveness profile of bimekizumab in patients affected by moderate-to-severe plaque psoriasis with involvement of genitalia. Methods: Bimekizumab, a dual inhibitor of both IL-17A and IL-17F, was the focus of our 16-week study, demonstrating highly favorable outcomes for patients with genital psoriasis. The effectiveness of bimekizumab was evaluated in terms of improvement in Static Physician's Global Assessment of Genitalia (sPGA-G) and Psoriasis Area and Severity Index. Results: Sixty-five adult patients were enrolled. Remarkably, 98.4% of our participants achieved a clear sPGA-G score (s-PGA-g=0) within 16 weeks. Moreover, consistent improvements were observed in PASI scores, accompanied by a significant reduction in the mean Dermatology Life Quality Index (DLQI), signifying enhanced quality of life. Notably, none of the patients reported a severe impairment in their quality of life after 16 weeks of treatment. In our cohort of 65 patients, subgroup analyses unveiled that the effectiveness of bimekizumab remained unaffected by prior exposure to other biologics or by obesity. Conclusions: Our initial findings suggest that bimekizumab may serve as a valuable treatment option for genital psoriasis. Nevertheless, further research with larger sample sizes and longer-term follow-up is imperative to conclusively validate these results.
- Published
- 2024
- Full Text
- View/download PDF
16. Bois noir management in vineyard: a review on effective and promising control strategies
- Author
-
Roberto Pierro, Abdelhameed Moussa, Nicola Mori, Carmine Marcone, Fabio Quaglino, and Gianfranco Romanazzi
- Subjects
'Candidatus Phytoplasma solani’ ,grapevine yellows ,insect vectors ,phytoplasma diseases ,sustainable management strategies ,Plant culture ,SB1-1110 - Abstract
Among grapevine yellows, Bois noir (BN), associated with ‘Candidatus Phytoplasma solani’, represents the biggest threat in the main wine-growing areas worldwide, causing significant losses in berry quality and yields. BN epidemiology involves multiple plant hosts and several insect vectors, making considerably complex the development of effective management strategies. Since application of insecticides on the grapevine canopy is not effective to manage vectors, BN management includes an integrated approach based on treatments to the canopy to make the plant more resistant to the pathogen and/or inhibit the vector feeding, and actions on reservoir plants to reduce possibilities that the vector reaches the grapevine and transmit the phytoplasma. Innovative sustainable strategies developed in the last twenty years to improve the BN management are reviewed and discussed.
- Published
- 2024
- Full Text
- View/download PDF
17. Space-time multilevel quadrature methods and their application for cardiac electrophysiology
- Author
-
Bader, Seif Ben, Harbrecht, Helmut, Krause, Rolf, Multerer, Michael, Quaglino, Alessio, and Schmidlin, Marc
- Subjects
Mathematics - Numerical Analysis ,Computer Science - Computational Engineering, Finance, and Science - Abstract
We present a novel approach which aims at high-performance uncertainty quantification for cardiac electrophysiology simulations. Employing the monodomain equation to model the transmembrane potential inside the cardiac cells, we evaluate the effect of spatially correlated perturbations of the heart fibers on the statistics of the resulting quantities of interest. Our methodology relies on a close integration of multilevel quadrature methods, parallel iterative solvers and space-time finite element discretizations, allowing for a fully parallelized framework in space, time and stochastics. Extensive numerical studies are presented to evaluate convergence rates and to compare the performance of classical Monte Carlo methods such as standard Monte Carlo (MC) and quasi-Monte Carlo (QMC), as well as multilevel strategies, i.e. multilevel Monte Carlo (MLMC) and multilevel quasi-Monte Carlo (MLQMC) on hierarchies of nested meshes. Finally, we employ a recently suggested variant of the multilevel approach for non-nested meshes to deal with a realistic heart geometry.
- Published
- 2021
18. The Skin Microbiome and Its Role in Psoriasis: A Review
- Author
-
Celoria V, Rosset F, Pala V, Dapavo P, Ribero S, Quaglino P, and Mastorino L
- Subjects
psoriasis ,skin microbiome ,new therapies ,gut microbioma ,molecular precision medicines ,next generation treatments. ,Dermatology ,RL1-803 - Abstract
Valentina Celoria,* Francois Rosset,* Valentina Pala, Paolo Dapavo, Simone Ribero, Pietro Quaglino, Luca Mastorino Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy*These authors contributed equally to this workCorrespondence: Valentina Celoria, Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy, Email valentina.celoria@edu.unito.itAbstract: The skin microbiome is made of various microorganisms, most of which have the function of protecting individuals from harmful pathogens, and they are involved in innate and adaptive immune responses. The skin acts as a physical and immunological barrier against external stimuli, including pathogens and physical damage. Changes in the composition of the skin microbiome can trigger inflammatory processes leading to inflammatory skin diseases in susceptible individuals. Psoriasis (PsO) is a chronic inflammatory disease with a multifactorial etiology, where breakdown of immune tolerance to cutaneous microorganisms is implicated in its pathogenesis. Dysregulation of the microbiome due to genetic and environmental factors plays a significant role in the development of psoriatic disease. Dermatologic conditions such as atopic dermatitis, acne, psoriasis, and rosacea have been associated with intestinal dysbiosis. The skin microbiota composition is crucial for the development of appropriate immune responses, and alterations in the skin microbiome can contribute to changes in physiology and susceptibility to skin diseases or inflammatory conditions. Understanding the microbial settlement of the skin and the network of interactions that occur throughout life is essential for comprehending the pathogenesis of skin diseases and developing innovative treatments. With this article we tried to explore the relationship between the human microbiome and psoriatic disease, shedding light on the functions of the microbiome and the inflammatory disease processes to identify additional therapeutic targets. This review aims to highlight the relationship between skin and gut microbiome functions and inflammatory processes in skin psoriasis and psoriatic arthritis (PsA). The goal is to facilitate future studies on the skin microbiome to identify potential novel therapies for patients with psoriatic disease.Keywords: psoriasis, skin microbiome, new therapies, gut microbiome, molecular precision medicines, next generation treatments
- Published
- 2023
19. Validation of airway porcine epithelial cells as an alternative to human in vitro preclinical studies
- Author
-
Vincenzo Giuseppe Genna, Davide Adamo, Giulia Galaverni, Fabio Lepore, Federica Boraldi, Daniela Quaglino, Filippo Lococo, and Graziella Pellegrini
- Subjects
Medicine ,Science - Abstract
Abstract Animal models are currently used in several fields of biomedical research as useful alternatives to human-based studies. However, the obtained results do not always effectively translate into clinical applications, due to interspecies anatomical and physiological differences. Detailed comparability studies are therefore required to verify whether the selected animal species could be a representative model for the disease or for cellular process under investigation. This has proven to be fundamental to obtaining reliable data from preclinical studies. Among the different species, swine is deemed an excellent animal model in many fields of biological research, and has been largely used in respiratory medicine, considering the high homology between human and swine airways. In the context of in vitro studies, the validation of porcine airway epithelial cells as an alternative to human epithelial cells is crucial. In this paper, porcine and human tracheal and bronchial epithelial cells are compared in terms of in vivo tissue architecture and in vitro cell behaviour under standard and airlifted conditions, analyzing the regenerative, proliferative and differentiative potentials of these cells. We report multiple analogies between the two species, validating the employment of porcine airway epithelial cells for most in vitro preclinical studies, although with some limitations due to species-related divergences.
- Published
- 2023
- Full Text
- View/download PDF
20. Epidemiology of cutaneous T-cell lymphomas: state of the art and a focus on the Italian Marche region
- Author
-
Pileri, Alessandro, Morsia, Erika, Zengarini, Corrado, Torre, Elena, Goteri, Gaia, Quaglino, Pietro, Pimpinelli, Nicola, Paulli, Marco, Pileri, Stefano A., Zinzani, Pier Luigi, and Rupoli, Serena
- Published
- 2023
- Full Text
- View/download PDF
21. Properties of the Estimators of the Cox Regression Model with Imputed Data
- Author
-
Chiapella, Luciana Carla, Quaglino, Marta Beatriz, and Mamprin, María Eugenia
- Published
- 2023
- Full Text
- View/download PDF
22. The Role of Fibroblasts in Skin Homeostasis and Repair
- Author
-
Federica Boraldi, Francesco Demetrio Lofaro, Susanna Bonacorsi, Alessia Mazzilli, Maria Garcia-Fernandez, and Daniela Quaglino
- Subjects
fibroblast ,extracellular matrix ,mechanobiology ,aging ,skin repair ,disease ,Biology (General) ,QH301-705.5 - Abstract
Fibroblasts are typical mesenchymal cells widely distributed throughout the human body where they (1) synthesise and maintain the extracellular matrix, ensuring the structural role of soft connective tissues; (2) secrete cytokines and growth factors; (3) communicate with each other and with other cell types, acting as signalling source for stem cell niches; and (4) are involved in tissue remodelling, wound healing, fibrosis, and cancer. This review focuses on the developmental heterogeneity of dermal fibroblasts, on their ability to sense changes in biomechanical properties of the surrounding extracellular matrix, and on their role in aging, in skin repair, in pathologic conditions and in tumour development. Moreover, we describe the use of fibroblasts in different models (e.g., in vivo animal models and in vitro systems from 2D to 6D cultures) for tissue bioengineering and the informative potential of high-throughput assays for the study of fibroblasts under different disease contexts for personalized healthcare and regenerative medicine applications.
- Published
- 2024
- Full Text
- View/download PDF
23. Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience
- Author
-
Luca Mastorino, Paolo Dapavo, Caterina Cariti, Sara Susca, Niccolò Siliquini, Michela Ortoncelli, Elena Stroppiana, Anna Verrone, Isotta Giunipero di Corteranzo, Francesco Leo, Pietro Quaglino, and Simone Ribero
- Subjects
psoriasis ,secukinumab ,PASI ,effectiveness ,5 years ,long term ,Medicine - Abstract
Introduction: the selective IL-17 inhibitor secukinumab has demonstrated efficacy and safety in the treatment of moderate–severe psoriasis in recent years. Objective: evaluate effectiveness and drug survival (DS) of secukinumab in patients with psoriasis for up to 5 years. Methods: This is a retrospective study on a monocentric cohort of patients with psoriasis on secukinumab evaluating the achievement of PASI100, PASI90, and PASI ≤ 3 and DS analysis up to 260 weeks. DS multivariate analysis was carried out considering sex, age, age of onset of the disease, obesity, cardiovascular comorbidities, diabetes, involvement of difficult-to-treat sites, psoriatic arthritis, treatment-naïve status, and mean baseline PASI. Results: At baseline, we evaluated 255 patients on secukinumab. PASI100 was reached by 41.7% and 70.6% of patients at weeks 16 and 260, respectively. PASI90 showed a similar trend with 46.5% of patients achieving it at week 16 and 88.2% at week 260. Non-obese patients showed a faster response than patients with obesity in achieving PASI100, PASI90, and PASI ≤ 3, with significant differences at 28 weeks [55% vs. 40% (p = 0.033), 64% vs. 49% (p = 0.038), and 76% vs. 62% (p = 0.036), respectively]. The estimated DS for secukinumab was 84.3% at 12 and 48% at 60 months. Obesity and smoking habits were associated with a higher risk of discontinuation in multivariate models (HR 1.6 CI 1.05–2.45, p = 0.028; HR 1.48 CI 1.01–2.17, p = 0.043, respectively). Conclusions: Secukinumab showed effectiveness for up to 5 years of treatment, with a high DS and achievement of PASI100, PASI90, and PASI < 3 at these time points. Only obesity reduced the response and maintenance of DS.
- Published
- 2024
- Full Text
- View/download PDF
24. I Won’t Forget to Do It If It’s Important: A Multinomial Processing Tree Analysis of Social Importance and Monetary Reward on Event-Based Prospective Memory
- Author
-
Geoffrey Blondelle, Véronique Quaglino, Yannick Gounden, Anaïs Dethoor, Harmony Duclos, and Mathieu Hainselin
- Subjects
prospective memory ,motivation ,mathematical modelling ,Consciousness. Cognition ,BF309-499 - Abstract
While previous research has suggested that prospective memory may be enhanced by providing a social motive (i.e., social importance) or by promising a monetary reward for successful performance, to the best of our knowledge, the underlying mechanisms responsible for these effects are still largely unexplored. In a sample of 96 younger adults, this study investigated how social importance and promising a monetary reward influence the prospective component and the retrospective component of event-based prospective memory separately, with the application of a multinomial modeling approach. Results revealed enhanced prospective memory performance for all importance conditions compared to a standard condition. This improvement was characterized by an increased allocation of resource-demanding attentional processes in performing the prospective memory task at the expense of the ongoing task without an increase in the perceived importance of the prospective memory task. The model-based analyses showed that the beneficial effects of importance arise from an increased engagement of the prospective component, leaving the estimates for the retrospective component unaffected.
- Published
- 2024
- Full Text
- View/download PDF
25. Eosinophilic Dermatosis of Hematologic Malignancy: Emerging Evidence for the Role of Insect Bites—A Retrospective Clinico-Pathological Study of 35 Cases
- Author
-
Andrea Michelerio, Marco Rubatto, Gabriele Roccuzzo, Marta Coscia, Pietro Quaglino, and Carlo Tomasini
- Subjects
eosinophilic dermatosis ,insect bites ,b cell chronic lymphocytic leukemia ,non-Hodgkin lymphoma ,eosinophils ,Wells syndrome ,Medicine - Abstract
Background/Objectives: Eosinophilic dermatosis of hematologic malignancy (EDHM) is a rare cutaneous disorder associated with various hematologic malignancies, most commonly chronic lymphocytic leukemia. Detailed clinicopathologic studies of EDHM are lacking and the pathogenesis remains enigmatic. Initially thought to be a hypersensitivity reaction to insect stings, subsequent reports have challenged this understanding. The prognostic implications of EDHM remain unclear. Methods: A retrospective clinicopathologic study was performed on patients diagnosed with EDHM. Hematologic and dermatologic data were reviewed. Histologic specimens were re-evaluated and lesions were classified into acute/subacute, fully developed, and chronic/regressing. Results: The study included 35 patients. In 80% of these patients, EDHM was diagnosed after the hematologic disorder. Approximately 45% of the cohort experienced hematologic disease progression or relapse, while 65% required therapeutic intervention during the course of their hematologic disease. In total, 15/19 CLL patients had non-mutated IgHV, a marker of a more aggressive hematologic disease course. Dermatologic lesion morphology was heterogeneous, with most lesions occurring on exposed areas, and a significant 94% of patients demonstrated lesion seasonality. Histopathologic findings were consistent with features typically associated with insect bites. In addition, examination of lesions at different chronological stages revealed substantial similarities with Wells syndrome. Conclusions: Our findings support the potential role of insect bites in triggering EDHM in the context of adaptive immune dysfunction. EDHM may be associated with a more aggressive disease course or may be a marker of disease progression. The observed co-occurrence of features typical of Wells syndrome in EDHM patients suggests that these conditions are part of a spectrum of disorders that vary in clinical expression.
- Published
- 2024
- Full Text
- View/download PDF
26. Effectiveness and tolerability of chlormethine gel for the management of mycosis fungoides: a multicenter real-life evaluation
- Author
-
Silvia Alberti-Violetti, Marco Ardigò, Cesare Massone, Alessandro Pileri, Raffaella Sala, Miriam Teoli, Vieri Grandi, Pietro Quaglino, Nicola Pimpinelli, and Emilio Berti
- Subjects
chlormethine gel ,CL gel ,mycosis fungoides ,MF ,cutaneous T-cell lymphoma ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundTopical chlormethine (CL) is recommended as a first-line treatment for early-stage mycosis fungoides (MF) and in 2017, the European Medicines Agency approved the CL gel formulation to treat adult patients. More recently, to increase patient compliance and adherence, clinicians have developed flexible protocols that allow the concomitant use of CL gel with topical corticosteroids in daily practice regimens. Therefore, sharing real-life data on CL gel use and side effects management may help improve the use of this agent.ObjectivesTo expand knowledge about the actual use of CL gel in patients with MF, the present study assessed the improvement of MF skin lesions after CL gel treatment and provided information on the management of cutaneous adverse events (AEs) in a real-life setting.MethodsThis was an Italian retrospective study conducted among six dermatology referral centers. Patients ≥18 years affected by MF and in treatment with CL gel (160 µ/g), alone or in combination according to routine clinical practice, between December 2019 and December 2021 were considered. The study’s primary aim was to evaluate the effectiveness of CL gel in terms of overall response rate (ORR) after 3 months of treatment.ResultsA total of 79 patients (61% male) with different stages of MF (84% early stage) were included. CL gel was prescribed mainly in association with topical corticosteroids (66% of patients). ORR after 3 months of treatment was 42%, with no differences between early- and advanced-stage MF. Response rates improved over time up to 97% after 18 months of treatment. Overall, 66 AEs were reported in 67% of patients; most were hyperpigmentation (45%) and irritant contact dermatitis (37%). Six AEs led to treatment discontinuation, and five out of six (83%) patients who reported these events resumed treatment after interruption. No AEs were classified as severe.ConclusionsOur observations support the use of CL gel in patients with early- and advanced-stage MF, making it a valuable treatment option.
- Published
- 2024
- Full Text
- View/download PDF
27. Efficient wastewater sample filtration improves the detection of SARS-CoV-2 variants: An extensive analysis based on sequencing parameters
- Author
-
Angelo Robotto, Carlotta Olivero, Elisa Pozzi, Claudia Strumia, Camilla Crasà, Cristina Fedele, Maddalena Derosa, Massimo Di Martino, Stefania Latino, Giada Scorza, Andrea Civra, David Lembo, Paola Quaglino, Enrico Brizio, and Denis Polato
- Subjects
Medicine ,Science - Published
- 2024
28. Clinical and Histopathological Findings in Palmoplantar Lichen Planus Presenting as Diffuse Keratoderma
- Author
-
Gianluca Avallone, Isotta Giunipero di Corteranzo, Rebecca Senetta, Gabriele Roccuzzo, Pietro Quaglino, and Simone Ribero
- Subjects
lichen planus ,palmoplantar lichen planus ,lichenoid dermatitis ,keratoderma ,palms ,Dermatology ,RL1-803 - Published
- 2024
- Full Text
- View/download PDF
29. Real-time Classification from Short Event-Camera Streams using Input-filtering Neural ODEs
- Author
-
Giannone, Giorgio, Anoosheh, Asha, Quaglino, Alessio, D'Oro, Pierluca, Gallieri, Marco, and Masci, Jonathan
- Subjects
Computer Science - Computer Vision and Pattern Recognition ,Computer Science - Neural and Evolutionary Computing - Abstract
Event-based cameras are novel, efficient sensors inspired by the human vision system, generating an asynchronous, pixel-wise stream of data. Learning from such data is generally performed through heavy preprocessing and event integration into images. This requires buffering of possibly long sequences and can limit the response time of the inference system. In this work, we instead propose to directly use events from a DVS camera, a stream of intensity changes and their spatial coordinates. This sequence is used as the input for a novel \emph{asynchronous} RNN-like architecture, the Input-filtering Neural ODEs (INODE). This is inspired by the dynamical systems and filtering literature. INODE is an extension of Neural ODEs (NODE) that allows for input signals to be continuously fed to the network, like in filtering. The approach naturally handles batches of time series with irregular time-stamps by implementing a batch forward Euler solver. INODE is trained like a standard RNN, it learns to discriminate short event sequences and to perform event-by-event online inference. We demonstrate our approach on a series of classification tasks, comparing against a set of LSTM baselines. We show that, independently of the camera resolution, INODE can outperform the baselines by a large margin on the ASL task and it's on par with a much larger LSTM for the NCALTECH task. Finally, we show that INODE is accurate even when provided with very few events., Comment: Submitted to ICML 2020
- Published
- 2020
30. Neural Lyapunov Model Predictive Control: Learning Safe Global Controllers from Sub-optimal Examples
- Author
-
Mittal, Mayank, Gallieri, Marco, Quaglino, Alessio, Salehian, Seyed Sina Mirrazavi, and Koutník, Jan
- Subjects
Computer Science - Artificial Intelligence ,Computer Science - Neural and Evolutionary Computing ,Electrical Engineering and Systems Science - Systems and Control - Abstract
With a growing interest in data-driven control techniques, Model Predictive Control (MPC) provides an opportunity to exploit the surplus of data reliably, particularly while taking safety and stability into account. In many real-world and industrial applications, it is typical to have an existing control strategy, for instance, execution from a human operator. The objective of this work is to improve upon this unknown, safe but suboptimal policy by learning a new controller that retains safety and stability. Learning how to be safe is achieved directly from data and from a knowledge of the system constraints. The proposed algorithm alternatively learns the terminal cost and updates the MPC parameters according to a stability metric. The terminal cost is constructed as a Lyapunov function neural network with the aim of recovering or extending the stable region of the initial demonstrator using a short prediction horizon. Theorems that characterize the stability and performance of the learned MPC in the bearing of model uncertainties and sub-optimality due to function approximation are presented. The efficacy of the proposed algorithm is demonstrated on non-linear continuous control tasks with soft constraints. The proposed approach can improve upon the initial demonstrator also in practice and achieve better stability than popular reinforcement learning baselines.
- Published
- 2020
31. Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis
- Author
-
L. Mastorino, F. Gelato, P. Quaglino, M. Ortoncelli, and S. Ribero
- Subjects
Dermatology ,RL1-803 - Published
- 2023
- Full Text
- View/download PDF
32. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyResearch in context
- Author
-
Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, and Keith T. Flaherty
- Subjects
Adjuvant therapy ,BRAF V600 mutation ,Melanoma ,PD-1 ,Dabrafenib/trametinib ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative data. We aimed to describe efficacy and toxicity outcomes for these two standard therapies across melanoma centers. Methods: This multicenter, retrospective cohort study was conducted in 15 melanoma centers in Australia, China, Germany, Italy, Japan, UK, and US. We included adult patients with resected stage III BRAF V600-mutant melanoma who received either adjuvant D/T or PD-1 between Jul 2015 and Oct 2022. The primary endpoint was relapse-free survival (RFS). Secondary endpoints included overall survival (OS), recurrence pattern and toxicity. Findings: We included 598 patients with stage III BRAF V600-mutant melanoma who received either adjuvant D/T (n = 393 [66%]) or PD-1 (n = 205 [34%]) post definitive surgery between Jul 2015 and Oct 2022. At a median follow-up of 33 months (IQR 21–43), the median RFS was 51.0 months (95% CI 41.0-not reached [NR]) in the D/T group, significantly longer than PD-1 (44.8 months [95% CI 28.5-NR]) (univariate: HR 0.66, 95% CI 0.50–0.87, P = 0.003; multivariate: HR 0.58, 95% CI 0.39–0.86, P = 0.007), with comparable OS with PD-1 (multivariate, HR 0.90, 95% CI 0.48–1.70, P = 0.75). Similar findings were observed using a restricted-mean-survival-time model. Among those who experienced recurrence, the proportion of distant metastases was higher in the D/T cohort. D/T had a higher incidence of treatment modification due to adverse events (AEs) than PD-1, but fewer persistent AEs. Interpretation: In patients with stage III BRAF V600-mutant melanoma post definitive surgery, D/T yielded better RFS than PD-1, with higher transient but lower persistent toxicity, and comparable OS. D/T seems to provide a better outcome compared with PD-1, but a longer follow-up and ideally a large prospective trial are needed. Funding: Dr. Xue Bai was supported by the Beijing Hospitals Authority Youth Programme (QMS20211101) for her efforts devoted to this study. Dr. Keith T. Flaherty was funded by Adelson Medical Research Foundation for the efforts devoted to this study.
- Published
- 2023
- Full Text
- View/download PDF
33. Aged gastrocnemius muscle of mice positively responds to a late onset adapted physical training
- Author
-
Barbara Cisterna, Francesco Demetrio Lofaro, Maria Assunta Lacavalla, Federico Boschi, Manuela Malatesta, Daniela Quaglino, Carlo Zancanaro, and Federica Boraldi
- Subjects
ageing ,skeletal muscle ,physical training ,matrix ,proteomics ,electron microscopy ,Biology (General) ,QH301-705.5 - Abstract
Introduction: A regular physical training is known to contribute to preserve muscle mass and strength, maintaining structure and function of neural and vascular compartments and preventing muscle insulin resistance and inflammation. However, physical activity is progressively reduced during aging causing mobility limitations and poor quality of life. Although physical exercise for rehabilitation purposes (e.g., after fractures or cardiovascular events) or simply aiming to counteract the development of sarcopenia is frequently advised by physicians, nevertheless few data are available on the targets and the global effects on the muscle organ of adapted exercise especially if started at old age.Methods: To contribute answering this question for medical translational purposes, the proteomic profile of the gastrocnemius muscle was analyzed in 24-month-old mice undergoing adapted physical training on a treadmill for 12 weeks or kept under a sedentary lifestyle condition. Proteomic data were implemented by morphological and morphometrical ultrastructural evaluations.Results and Discussion: Data demonstrate that muscles can respond to adapted physical training started at old age, positively modulating their morphology and the proteomic profile fostering protective and saving mechanisms either involving the extracellular compartment as well as muscle cell components and pathways (i.e., mitochondrial processes, cytoplasmic translation pathways, chaperone-dependent protein refolding, regulation of skeletal muscle contraction). Therefore, this study provides important insights on the targets of adapted physical training, which can be regarded as suitable benchmarks for future in vivo studies further exploring the effects of this type of physical activity by functional/metabolic approaches.
- Published
- 2023
- Full Text
- View/download PDF
34. Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
- Author
-
Kim, Youn H, Prince, H Miles, Whittaker, Sean, Horwitz, Steven M, Duvic, Madeleine, Bechter, Oliver, Sanches, Jose A, Stadler, Rudolf, Scarisbrick, Julia, Quaglino, Pietro, Zinzani, Pier Luigi, Wolter, Pascal, Eradat, Herbert, Pinter-Brown, Lauren C, Ortiz-Romero, Pablo L, Akilov, Oleg E, Trotman, Judith, Taylor, Kerry, Weichenthal, Michael, Walewski, Jan, Fisher, David, McNeeley, Marise, Gru, Alejandro A, Brown, Lisa, Palanca-Wessels, M Corinna, Lisano, Julie, Onsum, Matthew, Bunn, Veronica, Little, Meredith, Trepicchio, William L, and Dummer, Reinhard
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Oncology and Carcinogenesis ,Rare Diseases ,Lymphoma ,Clinical Research ,Hematology ,Orphan Drug ,Cancer ,Adult ,Aged ,Aged ,80 and over ,Antineoplastic Agents ,Immunological ,Brentuximab Vedotin ,Choice Behavior ,Decision Support Techniques ,Female ,Follow-Up Studies ,Humans ,International Agencies ,Ki-1 Antigen ,Male ,Middle Aged ,Mycosis Fungoides ,Physicians ,Prognosis ,Retrospective Studies ,Survival Rate ,Young Adult ,Antibody-drug conjugate ,Brentuximab vedotin ,CD30 ,Cutaneous T-cell lymphoma ,Efficacy ,Large-cell transformation ,Mycosis fungoides ,Objective response ,Progression-free survival ,Safety ,Public Health and Health Services ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
IntroductionMycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, can lead to disfiguring lesions, debilitating pruritus and frequent skin infections. This study assessed response to brentuximab vedotin in patients with MF in the phase III ALCANZA study.MethodsBaseline CD30 levels and large-cell transformation (LCT) status were centrally reviewed in patients with previously-treated CD30-positive MF using ≥2 skin biopsies obtained at screening; eligible patients required ≥1 biopsy with ≥10% CD30 expression. Patients were categorised as CD30min
- Published
- 2021
35. Safe Interactive Model-Based Learning
- Author
-
Gallieri, Marco, Salehian, Seyed Sina Mirrazavi, Toklu, Nihat Engin, Quaglino, Alessio, Masci, Jonathan, Koutník, Jan, and Gomez, Faustino
- Subjects
Electrical Engineering and Systems Science - Systems and Control ,Computer Science - Machine Learning ,Computer Science - Neural and Evolutionary Computing - Abstract
Control applications present hard operational constraints. A violation of these can result in unsafe behavior. This paper introduces Safe Interactive Model Based Learning (SiMBL), a framework to refine an existing controller and a system model while operating on the real environment. SiMBL is composed of the following trainable components: a Lyapunov function, which determines a safe set; a safe control policy; and a Bayesian RNN forward model. A min-max control framework, based on alternate minimisation and backpropagation through the forward model, is used for the offline computation of the controller and the safe set. Safety is formally verified a-posteriori with a probabilistic method that utilizes the Noise Contrastive Priors (NPC) idea to build a Bayesian RNN forward model with an additive state uncertainty estimate which is large outside the training data distribution. Iterative refinement of the model and the safe set is achieved thanks to a novel loss that conditions the uncertainty estimates of the new model to be close to the current one. The learned safe set and model can also be used for safe exploration, i.e., to collect data within the safe invariant set, for which a simple one-step MPC is proposed. The single components are tested on the simulation of an inverted pendulum with limited torque and stability region, showing that iteratively adding more data can improve the model, the controller and the size of the safe region., Comment: NeurIPS 2019 workshop on Safety and Robustness in Decision-Making
- Published
- 2019
36. Space-time multilevel Monte Carlo methods and their application to cardiac electrophysiology
- Author
-
Bader, Seif Ben, Benedusi, Pietro, Quaglino, Alessio, Zulian, Patrick, and Krause, Rolf
- Subjects
Computer Science - Computational Engineering, Finance, and Science ,Mathematics - Analysis of PDEs ,Mathematics - Numerical Analysis - Abstract
We present a novel approach aimed at high-performance uncertainty quantification for time-dependent problems governed by partial differential equations. In particular, we consider input uncertainties described by a Karhunen-Loeeve expansion and compute statistics of high-dimensional quantities-of-interest, such as the cardiac activation potential. Our methodology relies on a close integration of multilevel Monte Carlo methods, parallel iterative solvers, and a space-time discretization. This combination allows for space-time adaptivity, time-changing domains, and to take advantage of past samples to initialize the space-time solution. The resulting sequence of problems is distributed using a multilevel parallelization strategy, allocating batches of samples having different sizes to a different number of processors. We assess the performance of the proposed framework by showing in detail its application to the solution of nonlinear equations arising from cardiac electrophysiology. Specifically, we study the effect of spatially-correlated perturbations of the heart fibers conductivities on the mean and variance of the resulting activation map. As shown by the experiments, the theoretical rates of convergence of multilevel Monte Carlo are achieved. Moreover, the total computational work for a prescribed accuracy is reduced by an order of magnitude with respect to standard Monte Carlo methods.
- Published
- 2019
37. Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology
- Author
-
Queirolo, P., Cinquini, M., Argenziano, G., Bassetto, F., Bossi, P., Boutros, A., Clemente, C., de Giorgi, V., Del Vecchio, M., Patuzzo, R., Peris, K., Quaglino, P., Reali, A., Zalaudek, I., and Spagnolo, F.
- Published
- 2023
- Full Text
- View/download PDF
38. Ruta graveolens phytophotodermatitis
- Author
-
Avallone, Gianluca, Mastorino, Luca, Agostini, Andrea, Merli, Martina, Siliquini, Niccolò, Rubatto, Marco, Fierro, Maria Teresa, Ribero, Simone, and Quaglino, Pietro
- Subjects
photodermatitis ,phototoxicity ,phytophotodermatitis ,Rutaceae ,Ruta graveolens - Published
- 2021
39. Dupilumab in HIV-positive patients with atopic dermatitis: a long-term follow-up patient and a literature review
- Author
-
Avallone, Gianluca, Trunfio, Mattia, Giura, Maria Teresa, Siliquini, Niccolò, Viola, Riccardo, Orofino, Giancarlo, Mastorino, Luca, Ortoncelli, Michela, Quaglino, Pietro, and Ribero, Simone
- Subjects
antiretroviral therapy ,atopic dermatitis ,CD4 count ,dupilumab ,HIV ,viral load - Abstract
Dupilumab is an IgG4 human monoclonal antibody licensed for the treatment of moderate-to-severe atopic dermatitis. Despite evidence suggesting that T helper type two cytokines can modulate HIV-1 replication and anti-HIV-specific immune responses, impacting on viral reservoirs, HIV-positive patients under immunomodulating therapy have been excluded from clinical trials. We report a 47-year-old HIV-positive man with late-onset severe atopic dermatitis, treated with dupilumab and followed up for 27 months. Improvements in skin lesions and quality of life were observed after four months. Blood tests showed normalization of IgE levels, with the clinical condition remaining stable at a 27- month follow-up. We gathered 16 other cases reported in the literature of HIV-positive patients treated with dupilumab, with no, or few adverse reactions, for which it is unclear if dupilumab should be held accountable. With our case and literature review, we aim to shed light on dupilumab efficacy, safety, and tolerability among HIV-positive patients suffering from atopic dermatitis. In this regard, future research should focus on the effective role, underlying mechanisms, and efficacy of dupilumab in HIV-positive patients and HIV-positivity could be questioned as a valid exclusion criterion for clinical trials.
- Published
- 2021
40. Anti-laminin 332 antibody detection using biochip immunofluorescence microscopy in a real-life cohort of Italian patients with mucous membrane pemphigoid
- Author
-
Gasparini, Giulia, Cozzani, Emanuele, Di Zenzo, Giovanni, Salemme, Adele, Dematté, Eva, Vassallo, Camilla, Marzano, Angelo Valerio, Genovese, Giovanni, Caproni, Marzia, Antiga, Emiliano, Quaglino, Pietro, and Parodi, Aurora
- Published
- 2022
- Full Text
- View/download PDF
41. New insights on “bois noir” epidemiology in the Chianti Classico area (Tuscany, Central Italy)
- Author
-
Pierro, Roberto, Pedrelli, Athos, Marra, Monica, Matić, Slavica, Baldaccini, Luca, Materazzi, Alberto, Loni, Augusto, Lucchi, Andrea, Panattoni, Alessandra, Marcone, Carmine, and Quaglino, Fabio
- Published
- 2022
- Full Text
- View/download PDF
42. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
- Author
-
Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Antonio Cristaudo, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Francesca M. Gaiani, Paolo Gisondi, Alessandro Giunta, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Annamaria Offidani, Diego Orsini, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Piergiorgio Malagoli, and Antonio Costanzo
- Subjects
biologics ,bimekizumab ,psoriasis ,psoriasis treatment ,real-life ,Medicine (General) ,R5-920 - Abstract
IntroductionBimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited.MethodThis multicenter retrospective study included patients affected by plaque psoriasis treated with bimekizumab from May 1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients affected by moderate-to-severe plaque psoriasis eligible for systemic treatments were included. The effectiveness of bimekizumab was evaluated in terms of reduction in psoriasis area and severity index (PASI) compared with baseline at weeks 4 and 16. The main outcomes were the percentages of patients achieving an improvement of at least 75% (PASI75), 90% (PASI90) and 100% (PASI100) in PASI score.ResultsThe study included 237 patients who received at least one injection of bimekizumab. One hundred and seventy-one patients and 114 reached four and 16 weeks of follow-up, respectively. Complete skin clearance was achieved by 43.3% and 75.4% of patients at weeks 4 and 16, respectively. At week 16, 86.8% of patients reported no impact on their quality of life. At week 16, there were no significant differences between bio-naïve and bio-experienced patients in terms of PASI75, PASI90 and PASI100. The most commonly reported adverse events (AEs) were oral candidiasis (10.1%). No severe AEs or AEs leading to discontinuation were observed throughout the study.ConclusionOur experience supports the effectiveness and tolerability of bimekizumab in a real-world setting with similar results compared with phase-III clinical trials.
- Published
- 2023
- Full Text
- View/download PDF
43. SNODE: Spectral Discretization of Neural ODEs for System Identification
- Author
-
Quaglino, Alessio, Gallieri, Marco, Masci, Jonathan, and Koutník, Jan
- Subjects
Computer Science - Neural and Evolutionary Computing ,Computer Science - Machine Learning - Abstract
This paper proposes the use of spectral element methods \citep{canuto_spectral_1988} for fast and accurate training of Neural Ordinary Differential Equations (ODE-Nets; \citealp{Chen2018NeuralOD}) for system identification. This is achieved by expressing their dynamics as a truncated series of Legendre polynomials. The series coefficients, as well as the network weights, are computed by minimizing the weighted sum of the loss function and the violation of the ODE-Net dynamics. The problem is solved by coordinate descent that alternately minimizes, with respect to the coefficients and the weights, two unconstrained sub-problems using standard backpropagation and gradient methods. The resulting optimization scheme is fully time-parallel and results in a low memory footprint. Experimental comparison to standard methods, such as backpropagation through explicit solvers and the adjoint technique \citep{Chen2018NeuralOD}, on training surrogate models of small and medium-scale dynamical systems shows that it is at least one order of magnitude faster at reaching a comparable value of the loss function. The corresponding testing MSE is one order of magnitude smaller as well, suggesting generalization capabilities increase., Comment: Published as a conference paper at ICLR 2020
- Published
- 2019
44. Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas
- Author
-
Caruso L, Castellino A, Dessì D, Flenghi L, Giordano A, Ibatici A, Massone C, Pileri A, Proietti I, Pupo L, Quaglino P, Rupoli S, and Zinzani PL
- Subjects
cutaneous t- cell lymphoma ,mycosis fungoides ,sèzary sindrome ,mogamulizumab ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Laura Caruso,1 Alessia Castellino,2 Daniela Dessì,3 Leonardo Flenghi,4 Antonio Giordano,5 Adalberto Ibatici,6 Cesare Massone,7 Alessandro Pileri,8 Ilaria Proietti,9 Livio Pupo,10 Pietro Quaglino,11 Serena Rupoli,12 Pier Luigi Zinzani13,14 1Hematology and Bone Marrow Transplantation Unit, Azienda Ospedaliero Universitaria Policlinico G. Rodolico - San Marco Di Catania, Catania, Italy; 2Department of Hematology, Santa Croce E Carle Hospital, Cuneo, Italy; 3Department of Hematology, Businco Hospital Arnas AOB, Cagliari, Italy; 4Hematology and Bone Marrow Transplantation Unit, Santa Maria Della Misericordia Hospital, Perugia, Italy; 5Department of Hematology, Fondazione Policlinico Universitario Agostino Gemelli—IRCCS, Rome, Italy; 6Hematology and Transplant Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 7Dermatology Unit, Ospedali Galliera, Genova, Italy; 8Dermatology Unit, IRCCS S. Orsola-Malpighi Polyclinic, Bologna, Italy. Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum University of Bologna, Bologna, Italy; 9Dermatology Unit”Daniele Innocenzi”, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Terracina, Italy; 10UOC Lymphoproliferative Diseases, Fondazione PTV Policlinico Tor Vergata, Rome, Italy; 11Dermatologic Clinic, Department of Medical Sciences University of Turin Medical School, Turin, Italy; 12Clinic of Hematology, Ospedali Riuniti Ancona, Ancona, Italy; 13IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy; 14Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, ItalyCorrespondence: Pier Luigi Zinzani, IRCCS University Hospital of Bologna, Seràgnoli Institute of Hematology, and Department of Specialized, Diagnostic and Experimental Medicine, University of Bologna, via Massarenti 9, Bologna, 40138, Italy, Tel +39 051 2144042, Fax +39 051 2144037, Email pierluigi.zinzani@unibo.itAbstract: Mycosis fungoides and Sèzary syndrome are the most studied subtypes common cutaneous T-cell lymphomas. The current treatment objective is to improve the clinical manifestations of the disease in the affected areas, to relieve symptoms and to halt disease progression. Patients with early-stage mycosis fungoides are usually managed with skin-directed therapies, whereas patients with resistant or advanced-stage mycosis fungoides or Sèzary syndrome often require systemic drugs. Over the last decade, new drugs have been developed, increasing the breadth of treatment options for cutaneous T-cell lymphomas patients. Mogamulizumab is a first-in-class defucosylated humanized IgG1 κ monoclonal antibody, which exerts its anti-tumour action by selectively binding to C-C chemokine receptor 4 and increasing antibody-dependent cellular cytotoxicity activity against malignant T-cells. Several clinical trials showed that mogamulizumab is able to effectively control the cutaneous T-cell lymphomas in each site (skin, blood, lymph nodes and viscera), improving patients’ symptoms, function and overall quality of life with a manageable safety profile. In this report, we discuss 12 cases of patients with mycosis fungoides or Sèzary syndrome successfully treated with mogamulizumab in real-life clinical practice in Italy.Keywords: cutaneous T- cell lymphoma, mycosis fungoides, Sèzary syndrome, mogamulizumab
- Published
- 2022
45. Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice
- Author
-
Roccuzzo G, Mastorino L, Gallo G, Fava P, Ribero S, and Quaglino P
- Subjects
mycosis fungoides ,folliculotropic mycosis fungoides ,cutaneous lymphoma ,primary cutaneous t-cell lymphoma ,therapy ,Dermatology ,RL1-803 - Abstract
Gabriele Roccuzzo,* Luca Mastorino,* Giuseppe Gallo, Paolo Fava, Simone Ribero, Pietro Quaglino Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy*These authors contributed equally to this workCorrespondence: Giuseppe Gallo, Department of Medical Sciences, Section of Dermatology, University of Turin, Via Cherasco 23, Torino, Turin, 10126, Italy, Tel +39 0116335843 ; +39 0116335034, Email giuseppegallomd@gmail.comIntroduction: Folliculotropic mycosis fungoides (FMF) is the most frequent variant of mycosis fungoides (MF), with clinical features which differ from the classic form. As for therapeutic options, the latest guidelines on MF agree on a stage-driven strategy, in consideration of clinical presentation, symptom burden and patient’s comorbidities.Materials and Methods: A search on MEDLINE, PubMed, Scopus and Cochrane Library was conducted to gather the latest evidence on FMF clinical management. Manuscripts published in the last five years (January 2017–April 2022) were included. Our single-center experience was also described.Results: A total of 15 articles were analyzed, with a total of 432 patients (disease stage from IA to IVA2). The most widely-used treatment was psoralen ultra-violet A (PUVA) in monotherapy or in association with other drugs. Oral retinoid-based therapy was also described as a therapeutic option alone or in combination. Other therapy reported were based on Brentuximab Vedotin, Mogamulizumab, Carmustine, topical steroids, tazarotene and excimer laser, interferon, nitrogen mustard, imiquimod, systemic chemotherapy, extracorporeal photopheresis and stem cell transplantation.Discussion: FMF is characterized by specific clinical-pathologic features. Advanced forms assume characteristics more similar to classic MF (infiltrated plaques and nodules), whilst early stages can present in a wide range of clinical forms (acneiform lesions, follicular-like keratoses, erythematous patches). As for therapeutic options, in absence of specific guidelines, a high number of treatments are described in clinical practice, with variable results. Phototherapy in all its forms, especially as PUVA, appears to have the greatest initial therapeutic success. Retinoids, although widely used, appear to be poorly effective in monotherapy, particularly acitretin. Combination treatment with phototherapy seems to be advisable. Ionizing treatments, such as radiotherapy and TSEBT, appear effective, at least in the short term. Overall, an integrated approach is mandatory for the inconstant course of the disease and its multidisciplinary nature.Keywords: mycosis fungoides, folliculotropic mycosis fungoides, cutaneous lymphoma, primary cutaneous T-cell lymphoma, therapy
- Published
- 2022
46. Survey on phytoplasmas associated with grapevine yellows in Eastern Georgia, Caucasus region
- Author
-
Iveta Megrelishvili, Zurab Khidesheli, Tinatin Elbakidze, Levan Ujmajuridze, Fabio Quaglino, and Nino Maziashvili
- Subjects
bois noir ,detection ,flavescence dorée ,16srv ,Plant culture ,SB1-1110 - Abstract
During field surveys conducted from July to October 2018–2020 in the eastern part of Georgia (Caucasus region), 145 out of 8000 (1.8%) and 147 out of 6600 (2.2%) grapevine plants, respectively, from mother stock/collection fields and commercial vineyards, were found exhibiting typical or suspicious grapevine yellows (GY) symptoms. Most of the symptomatic grapevine plants of Georgian cultivars showed mild symptoms with no berry alterations. Leaf samples from symptomatic plants were analyzed by serological (DAS- -ELISA) and molecular (two previously published protocols of TaqMan triplex real-time PCR, here named Set I and Set II) tools for detecting GY-associated phytoplasmas. The presence of GY phytoplasmas was not detected in any examined grapevines by a serological method. GY phytoplasmas were identified in 22.41% and 6.9% symptomatic plants from mother stock and collection vineyards and in 48.3 and 19.0% symptomatic plants from commercial vineyards by Set I and Set II PCRs, respectively. As expected from previous studies reporting the wide presence of bois noir (BN) in Georgian vineyards, ‘Candidatus Phytoplasma solani’(CaPsol) was detected in most phytoplasma-infected plants (47.6%), with the highest infection rate in Chardonnay. Phytoplasmas belonging to taxonomic group 16SrV were detected in 45.6% of the phytoplasma-infected grapevines. To the best of our knowledge, this is the first report of 16SrV phytoplasmas in Georgia and in the Caucasus region. Further molecular typing of 16SrV phytoplasma strains is necessary to determine if such strains are associated with flavescence dorée (FD). The knowledge of typical GY symptoms and the utilization of accurate diagnostic tools are crucial for preventing pathogen spread and producing healthy planting material. Based on the results obtained in this study, the presence of BN and 16SrV phytoplasmas should be monitored in the next years using triplex real-time PCR.
- Published
- 2022
- Full Text
- View/download PDF
47. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience
- Author
-
Martina Merli, Martina Accorinti, Maurizio Romagnuolo, Angelo Marzano, Giovanni Di Zenzo, Francesco Moro, Emiliano Antiga, Roberto Maglie, Emanuele Cozzani, Aurora Parodi, Giulia Gasparini, Pietro Sollena, Clara De Simone, Marzia Caproni, Luigi Pisano, Davide Fattore, Riccardo Balestri, Paolo Sena, Pamela Vezzoli, Miriam Teoli, Marco Ardigò, Camilla Vassallo, Andrea Michelerio, Rosanna Rita Satta, Emi Dika, Barbara Melotti, Simone Ribero, and Pietro Quaglino
- Subjects
immunotherapy ,anti PD-1 ,anti PD-L1 ,cutaneous irAE ,bullous pemphigoid ,lichen planus pemphigoides ,Medicine (General) ,R5-920 - Abstract
Cutaneous immune-related adverse events are frequently associated with immune checkpoint inhibitors (ICIs) administration in cancer patients. In fact, these monoclonal antibodies bind the cytotoxic T-lymphocyte antigen-4 and programmed cell death-1/ligand 1 leading to a non-specific activation of the immune system against both tumoral cells and self-antigens. The skin is the most frequently affected organ system appearing involved especially by inflammatory manifestations such as maculopapular, lichenoid, psoriatic, and eczematous eruptions. Although less common, ICI-induced autoimmune blistering diseases have also been reported, with an estimated overall incidence of less than 5%. Bullous pemphigoid-like eruption is the predominant phenotype, while lichen planus pemphigoides, pemphigus vulgaris, and mucous membrane pemphigoid have been described anecdotally. Overall, they have a wide range of clinical presentations and often overlap with each other leading to a delayed diagnosis. Achieving adequate control of skin toxicity in these cases often requires immunosuppressive systemic therapies and/or interruption of ICI treatment, presenting a therapeutic challenge in the context of cancer management. In this study, we present a case series from Italy based on a multicenter, retrospective, observational study, which included 45 patients treated with ICIs who developed ICI-induced bullous pemphigoid. In addition, we performed a comprehensive review to identify the cases reported in the literature on ICI-induced autoimmune bullous diseases. Several theories seeking their underlying pathogenesis have been reported and this work aims to better understand what is known so far on this issue.
- Published
- 2023
- Full Text
- View/download PDF
48. Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience
- Author
-
Silvia Giordano, Paolo Dapavo, Michela Ortoncelli, Elena Stroppiana, Anna Verrone, Pietro Quaglino, Simone Ribero, and Luca Mastorino
- Subjects
psoriasis ,IL23 inhibitors ,IL17 inhibitors ,PASI ,switch ,switching ,Medicine - Abstract
Background: Interleukin 23 (IL-23) inhibitors, such as guselkumab, risankziumab, and tildrakizumab, have proved to be highly effective and safe for psoriasis treatment either in bio-naïve or bio-experienced patients. A substantial proportion of patients show a primary or secondary inefficacy to IL-17 inhibitors and can benefit from an alternative line of treatment, like IL-23 inhibitors. To date, no sufficient data are available on the effectiveness of IL-23 inhibitors after an anti-IL-17 agent. Methods: Our study includes 48 patients with moderate to severe psoriasis undergoing a switch from IL-17 to IL-23 inhibitors. This trial is registered with SS_DERMO_20. Results: The mean PASI (Psoriasis Area Severity Index) decreases from 11.6 to 3.3 at week 16, with responses maintained at weeks 28 and 52 (2 and 1.4, respectively), and a PASI100 achievement in more than 24% of patients at 16 weeks and 61.9 at 48 weeks, with no occurrence of serious adverse events. However, almost one in six patients interrupted the IL-23 inhibitors mainly due to primary ineffectivenss. Conclusions: Our data support the evidence that an interclass switch among IL-17 inhibitors is a safe and effective therapeutic option for these patients.
- Published
- 2023
- Full Text
- View/download PDF
49. Simultaneous Skin Rejuvenation in Patients Undergoing Medical Treatment for Actinic Keratosis and Non-Melanoma Skin Cancer: A Case Series Analysis
- Author
-
Nadia Sciamarrelli, François Rosset, Sara Boskovic, Silvia Borriello, Luca Mastorino, Simone Ribero, Pietro Quaglino, and Paolo Broganelli
- Subjects
skin rejuvenation ,actinic keratosis ,NMSC ,5-fluorouracil ,MAL-PDT ,Chemistry ,QD1-999 - Abstract
This original article presents the findings of a comprehensive case series, shedding light on the efficacy of diverse treatment modalities for managing precancerous and cancerous skin lesions and their remarkable rejuvenation effects on the skin. A particular focus is placed on the promising outcomes achieved through the application of a combination treatment involving 5-Fluorouracil (5-FU) and salicylic acid, which demonstrates enduring and noteworthy results. Furthermore, alternative therapeutic approaches, including 5-FU monotherapy, Methyl aminolevulinate–photodynamic therapy (MAL-PDT), and the combination of Imiquimod therapy with MAL-PDT, exhibit substantial potential for patients seeking non-surgical solutions. These treatments manifest as valuable tools in improving skin texture and mitigating the effects of photodamage. Nevertheless, the intricate interplay between the chosen treatment, the extent of photodamage, and individual patient characteristics, with a particular emphasis on age, necessitates long-term follow-up to gauge treatment outcomes and the likelihood of lesion recurrence. Notably, these treatments are associated with a significant degree of inflammation, igniting curiosity regarding enhanced skin cellular turnover and the potential for a more youthful skin appearance. Our findings accentuate the promise of topical fluorouracil (5-FU) and photodynamic therapy (PDT) in combating photoaging among patients with actinic keratoses. However, a need for further in-depth research is evident to unravel the nuanced relationships between these treatments, the severity of photodamage, and the influence of patient-specific factors. Such comprehensive investigations are instrumental in optimizing patient care and outcomes, offering a holistic approach to managing photodamage within the context of actinic keratoses. This work, when combined with existing literature, provides valuable insights and serves as a catalyst for future research to fully unlock the potential of these treatments, ultimately enhancing the quality of patient care.
- Published
- 2023
- Full Text
- View/download PDF
50. Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics
- Author
-
Valentina Pala, Simone Ribero, Pietro Quaglino, and Luca Mastorino
- Subjects
vitiligo ,hypopigmentation ,JAK inhibitors ,biologics ,Medicine - Abstract
Vitiligo, the most prevalent skin depigmenting disease, is characterized by the selective loss of melanocytes, impacting patients’ quality of life significantly. This autoimmune disorder progresses through a complex interplay of genetic and non-genetic factors, posing challenges in comprehending its pathogenesis and devising effective treatment strategies for achieving remission. Existing conventional therapeutic approaches, such as topical and oral corticosteroids, calcineurin inhibitors, and phototherapy, lack specificity, offer modest efficacy, and may entail potential adverse effects. Consequently, there is a pressing need for a more nuanced understanding of vitiligo’s pathogenesis to pave the way for targeted therapeutic innovations. This review aims to provide a comprehensive overview of recent developments and findings concerning Januse Kinase (JAK) inhibitors and biologics tested in vitiligo patients. JAK inhibitors have exhibited promising results, showcasing both efficacy and tolerability. In contrast, the outcomes of biologics treatment have been more varied. However, to establish a clearer understanding of which specific pathways to target for a more effective approach to vitiligo, additional in vitro studies and extensive clinical research involving a larger population are imperative.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.